What Are the Fundamentals Of NVO?

By Scott Lee • Tuesday, January 10 10:34 • Permanent Link

Large-cap Healthcare company Novo Nordisk A/S has moved -1.8% so far today on a volume of 362,287, compared to its average of 1,334,953. In contrast, the S&P 500 index moved -0.2%.

Novo Nordisk A/S trades 5.03% away from its average analyst target price of $128.29 per share. The 3 analysts following the stock have set target prices ranging from $120.08 to $134.69, and on average have given Novo Nordisk A/S a rating of strong buy.

If you are considering an investment in NVO, you'll want to know the following:

Novo Nordisk A/S's current price is 26.6% above its Graham number of $106.42, which implies that at its current valuation it does not offer a margin of safety
Based on its trailing earnings per share of 2.92, Novo Nordisk A/S has a trailing 12 month Price to Earnings (P/E) ratio of 46.1 while the S&P 500 average is 15.97
NVO has a forward P/E ratio of 40.1 based on its forward 12 month price to earnings (EPS) of $3.36 per share
The company has a price to earnings growth (PEG) ratio of 125.22 — a number near or below 1 signifying that Novo Nordisk A/S is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 4.9 compared to its sector average of 4.07
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.
Based in Bagsvaerd, the company has 50,816 full time employees and a market cap of $307,150,618,624. Novo Nordisk A/S currently returns an annual dividend yield of 6.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.